Lexicon Genetics Inc., of The Woodlands, Texas, appointed Barry Mills to its board.

Locus Pharmaceuticals Inc., of Blue Bell, Pa., appointed Howard Ball senior director of preclinical development.

Lux Biosciences Inc., of Jersey City, N.J., appointed David Guyer to its board.

Medicure Inc., of Winnipeg, Manitoba, appointed Charles Gluchowski vice president of research and development; and Kishore Kapoor to its board.

Metabolix Inc., of Cambridge, Mass., appointed Robert Findlen vice president, sales and marketing.

Nascent Pharmaceuticals Inc., of Research Triangle Park, N.C., appointed Joanna Horobin to its board.

Neogen Corp., of Lansing, Mich., appointed Lon Bohannon president and chief operating officer.

Nereus Pharmaceuticals Inc., of San Diego, appointed Charles White chief business officer.

NovaCal Pharmaceuticals Inc., of Emeryville, Calif., appointed Alex McPherson to its board.

Novavax Inc., of Malvern, Pa., appointed director John Marsh to the audit committee.

Nuvelo Inc., of San Carlos, Calif., appointed Gregory Yedinak vice president, manufacturing and process sciences; and Ralph Zitnik vice president, development.

Oncolytics Biotech Inc., of Calgary, Alberta, appointed Ger van Amersfoort to its board.

Oscient Pharmaceuticals Corp., of Waltham, Mass., appointed William Mattson to its board.

Oxigene Inc., of Waltham, Mass., appointed Richard Chin president and CEO.

Panacea Pharmaceuticals Inc., of Gaithersburg, Md., appointed Stephen Keith president and chief operating officer.

Penwest Pharmaceuticals Co., of Danbury, Conn., appointed Benjamin Palleiko senior vice president, corporate development and chief financial officer.

Peplin Ltd., of Queensland, Australia, appointed Cheri Jones vice president, regulatory affairs; and Gary Patou interim chief medical officer.

PeriCor Therapeutics Inc., of New York, appointed Robert Engler to its board.

PharmaFrontiers, of The Woodlands, Texas, appointed Michael Richman to its board.

Pheromone Sciences Corp., of Kelowna, British Columbia, appointed David White principal researcher of the company's diabetes research project and the chair of its scientific advisory board; Justin Leushner president; and Charles Allard to its board.

Poniard Pharmaceuticals Inc., of Seattle, appointed Caroline Loewy executive vice president, strategic planning and investor relations; Cheni Kwok vice president, business development; and Ronald Martell to its board.

Receptor BioLogix Inc., of South San Francisco, appointed Thomas Glaze CEO and a member of its board.

Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Brian Hayden senior vice president, chief financial officer and treasurer.

Sinovac Biotech Ltd., of Beijing, China, appointed Lo Yuk Lam, Mok Chup Hung and Xianping Wang to its board; and Jinling Qin acting chief financial officer.

Solexa Inc., of Hayward, Calif., appointed Richard Lussier vice president, sales and field operations.

Starpharma Holdings Ltd., of Melbourne, Australia, appointed Jackie Fairley CEO and member of its board, replacing John Raff.